Crispr per la prima volta modifica il dna al di fuori della cellula – Wired.it
Wired.it |
Crispr per la prima volta modifica il dna al di fuori della cellula
Wired.it Gli studi si basano in molti casi su CRISPR-Cas9, dove Cas9 è un enzima che funziona come vere e proprie forbici che tagliano a fette ed inseriscono parti di dna. Tuttavia questa tecnica è efficace nel modificare i geni all’interno della cellula … Editing genetico in provetta – AdnkronosAdnkronos |
Nantucket Island Inquirer |
‘Super Bowl of lung cancer immunotherapy‘
Nantucket Island Inquirer Lung cancer is the second-most-common malignancy in the United States, after breast cancer. The American Cancer Society estimates that 234,000 people will be diagnosed with the disease this year, and 154,050 will die of it. Patients with newly … Immunotherapy Might Improve Survival Outcomes in Late-Stage …WMFE Immunotherapy improves statistics of survival in lung cancer patientsPulse Headlines Opinion | The Problem With Miracle Cancer Cures – The New York …New York Times OncLive –WSYM-TV all 8 news articles » |
News-Medical.net |
Rounds Report: Crispr Rallied While FDA Developments Could Benefit Gene-Based Innovators
Seeking Alpha Harnessing the power of the CRISPR/Cas9 editing platform (as depicted in figure 2) – a mechanism perfected by bacteria as a defense tactic for millions of years – it’s highly favorable that the lead molecule (CTX-001) will post strong results for the … The First “Cell-Free” CRISPR Tech Is Here To Personalize Cancer TreatmentFuturism New CRISPR tool allows DNA editing outside of the cellNews-Medical.net ‘Cell-free’ CRISPR could improve cancer diagnostics, unravel how gene editing worksFierceBiotech Reason (blog) –EurekAlert (press release) –Gizmodo all 18 news articles » |
WMFE |
Immunotherapy Might Improve Survival Outcomes in Late-Stage …
WMFE A study in the New England Journal of Medicine found that immunotherapy could improve survival outcomes in patients with an aggressive form of lung cancer. Florida Hospital Cancer Institute’s Dr. Mark Socinski says the drug should be a first-line … Opinion | The Problem With Miracle Cancer Cures – The New York …New York Times Immunotherapy improves statistics of survival in lung cancer patientsPulse Headlines Hellman Expands on TMB Testing in Lung Cancer – OncLiveOncLive WSYM-TV all 7 news articles » |
Proactive Investors Australia |
Regeneus director supports stem cell technology through on-market purchase
Proactive Investors Australia Regeneus Ltd’s (ASX:RGS) recently appointed Japanese-based non-executive director, Leo Lee, has demonstrated his confidence in the company’s stem cell technology platform through an on-market purchase of shares. Lee purchased 1,011,000 shares for a … |